Was the drop in mammography rates in 2005 associated with the drop in hormone therapy use?

Division of Cancer Control and Population Sciences, National Institute, Bethesda, Maryland 20852-7344, USA.
Cancer (Impact Factor: 4.89). 12/2011; 117(24):5450-60. DOI: 10.1002/cncr.26218
Source: PubMed


In 2005, mammography rates in the United States dropped nationally for the first time among age-eligible women. An increased risk of breast cancer related to hormone therapy (HT) use reported in 2002 led to a dramatic drop in its use by 2005. Because current users of HT also tend to have higher mammography rates, the authors examined whether concurrent drops in HT and mammography use were associated.
Multivariate logistic regression was used to test for an interaction between HT use and survey year, controlling for a range of measurable factors in data from the 2000 and 2005 National Health Interview Surveys (NHIS).
Women ages 50 to 64 years were more likely to report a recent mammogram if they also reported more education, a usual source of care, private health insurance, any race except non-Hispanic Asian, talking with an obstetrician/gynecologist or other physician in the past 12 months, or were currently taking HT. Women aged ≥ 65 years were more likely to report a recent mammogram if they also reported younger age (ages 65-74 years), more education, a usual source of care, having Medicare Part B or other supplemental Medicare insurance, excellent health, any race except non-Hispanic Asian, talking with an obstetrician/gynecologist or other physician in the past 12 months, or were currently taking HT.
The change in HT use was associated with the drop in mammography use for women ages 50 to 64 years but not for women aged ≥ 65 years. NHIS data explained 70% to 80% of the change in mammography use.

Download full-text


Available from: Stephen H Taplin,
19 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: On January 1, 2005, Medicare began covering a "Welcome to Medicare" visit (WMV) for new enrollees with fee-for-service (FFS) Medicare (Parts A and B). The new benefit was expected to increase demand for mammography and Pap tests among women transitioning onto Medicare. This study examined whether Medicare's coverage of a WMV influenced the use of mammography and Pap tests among women aged 65 and 66 years with FFS Medicare. Methods: Medicare Current Beneficiary Survey (MCBS) data from 2001 to 2007 were linked with Medicare claims. Utilization rates for preventive visits, mammography, and Pap tests were measured among women entering Medicare. Multivariate logistic regressions were estimated to quantify the effects of the new Medicare benefit on the use of these screening tests, controlling for patient characteristics. Results: Regression-adjusted mammography and Pap test rates did not increase after WMV coverage was introduced. The 2005 reform had nonsignificant trivial effects on the use of both tests, most likely because few of the women who were eligible for a WMV took advantage of it. Conclusions: Medicare coverage of a WMV had no impact on mammography screenings or Pap tests among women who were eligible for the benefit.
    Journal of Women's Health 11/2012; 22(1). DOI:10.1089/jwh.2012.3777 · 2.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT Background: Several studies report a Breast Cancer (BC) incidence decrease subsequent to the decrease in Hormone replacement therapy (HRT) use. But its magnitude and the time-lag may vary between countries. This may reflect differences in populations, previous type and prevalence of HRT use and BC screening. Aim: To review systematically studies assessing the relation between BC incidence and change of HRT use. Material and method: Descriptive analysis of the methodology of the studies including design limitations and presence of confounding factors, data sources for BC and HRT and regimens of HRT used. Results and discussion: Eighteen articles were selected. Most studies were ecological and confounding factors such as mammography screening and changes in reproductive and life style habits could not be excluded. Sources of data on BC and HRT were heterogeneous and only few data on HRT regimens used were available. Most studies concluded that the decrease in HRT use during the last decade was probably associated with a BC incidence decrease, especially for women aged 50 or more. Conclusions: Data, mostly from epidemiological studies, suggest that the BC incidence decrease can be partly attributed to the HRT use drop. Nevertheless, available studies are hampered by a number of limitations and it remains difficult to evaluate the exact impact of HRT drop on BC incidence decrease. Especially, the studies are seldom based on detailed individual data and don't provide information on used regimens, type of cancers and possible confounding factors.
    Climacteric 08/2013; 17(2). DOI:10.3109/13697137.2013.829812 · 2.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Large-scale surveys that assess cancer prevention and control behaviors are a readily-available, rich resource for public health researchers. Although these data are used by a subset of researchers who are familiar with them, their potential is not fully realized by the research community for reasons including lack of awareness of the data, and limited understanding of their content, methodology, and utility. Until now, no comprehensive resource existed to describe and facilitate use of these data. To address this gap and maximize use of these data, we catalogued the characteristics and content of four surveys that assessed cancer screening behaviors in 2005, the most recent year with concurrent periods of data collection: the National Health Interview Survey, Health Information National Trends Survey, Behavioral Risk Factor Surveillance System, and California Health Interview Survey. We documented each survey's characteristics, measures of cancer screening, and relevant correlates; examined how published studies (n=78) have used the surveys' cancer screening data; and reviewed new cancer screening constructs measured in recent years. This information can guide researchers in deciding how to capitalize on the opportunities presented by these data resources.
    Cancer Epidemiology Biomarkers & Prevention 10/2014; DOI:10.1158/1055-9965.EPI-14-0568 · 4.13 Impact Factor
Show more